Video
25 Oct 2024
Comparative Study: Low-Volume Mixing Performance on Protein Formulation Shear Stress
.png)
In biologics production, mixing operations are crucial for maintaining fluid homogeneity. However, shear stress during mixing can affect protein stability and quality attributes. Understanding how mixer design and process parameters influence shear force generation is essential for product integrity.
Computational Fluid Dynamic (CFD) modeling during product development demonstrated that the Mixed4Sure™ Bottom Mount impeller design outperformed traditional stir bars. Subsequent laboratory evaluation using lysozyme as a protein model confirmed these findings.
This session will highlight the importance of innovative mixer designs in optimizing protein formulation processes that will help you maintain product quality. During the session, the following key takeaways will be discussed:
- CFD modeling revealed superior mixing performance of the new impeller geometry
- Laboratory studies validated the CFD predictions
- The Mixed4Sure™ Bottom Mount demonstrated lower shear stress compared to conventional stir bars, indicating improved mixing performance in shear sensitive process steps.
Content provided by our supplier
Sanisure
-
Country/Region:Luxembourg
-
On CPHI since:2023
-
Certificates:2
-
Employees:250 - 499
Company types
Primary activities
Other Content from Sanisure (11)
-
News Our Commitment to Sustainability
At SaniSure, we want to make sustainable corporate culture transparent.
EcoVadis Gold places SaniSure in the elite top 5% of rated organizations globally. -
Report Closed-System Automation: Solving Challenges in Vaccine and Viral Vector Manufacturing
Modernize vaccine and viral vector manufacturing with automated roller bottle processing that reduces contamination risk while meeting FDA and EU regulatory requirements.
As regulators and clients demand higher quality, faster timelines, and lower contamination risk, organizations relying on manual roller bottle processes face increasing pressure to modernize. Closed-system automation like the RC-40™ bridges the gap—offering a compliant, scalable solution without abandoning validated processes.
Download the GMP Compliance Checklist to benchmark your roller bottle operations and identify opportunities for improvement. Or, contact our technical team to explore how RC‑40 can address your specific compliance and efficiency challenges.
-
News Closed-System Automation: Solving Challenges in Vaccine and Viral Vector Manufacturing
Modernize vaccine and viral vector manufacturing with automated roller bottle processing that reduces contamination risk while meeting FDA and EU regulatory requirements. -
Video PharmaTainer™ Drop Test
Gamma-irradiated 10 L PharmaTainer™ bottles were filled to nominal volume and frozen to -80°C for 2 days. The bottles were then dropped two times in a row onto a flat concrete surface from a height of 110cm.
After the contents were thawed, leak tests were performed on the sides, base, and closure. All bottles passed the drop test with only minor scratches!
-
News Ensuring Nuclease-Free Process Consumables for Biopharma Applications
This white paper explores critical contamination control strategies and advanced containment solutions to protect sensitive mRNA and gene therapies in GMP biopharmaceutical manufacturing environments.
-
Whitepaper Setting the Weld Standard: Validating Cleargreen®Pure Tubing for Closed-System Bioprocessing
This white paper reviews a comprehensive TR-1092 study, demonstrating that ClearGreen®Pure outperforms leading PVC competitors in weld integrity, burst pressure, and particulate cleanliness for commercial cell therapy manufacturing. -
News Setting the Weld Standard: Validating Cleargreen®Pure Tubing for Closed-System Bioprocessing
Comprehensive TR-1092 study demonstrates ClearGreen®Pure outperforms leading PVC competitors in weld integrity, burst pressure, and particulate cleanliness for commercial cell therapy manufacturing.
-
Whitepaper Ensuring Nuclease-Free Process Consumables for Biopharma Applications
The rapid advancement of cell and gene therapies, particularly mRNA-based therapeutics, has created an unprecedented demand for nuclease-free manufacturing environments. Even trace amounts of DNase or RNase contamination can compromise critical materials and undermine therapeutic outcomes.
Through detailed analysis of container manufacturing processes, rigorous enzymatic testing protocols, and extensive validation procedures, the paper demonstrates how advanced technologies like PharmaTainer™ establish new standards for contamination control in GMP environments. The comprehensive analysis spans innovative manufacturing technologies and validation protocols essential for maintaining nuclease-free conditions across manufacturing scales from 10 mL to 20 L, particularly benefiting mRNA vaccine and gene therapy applications. This technical resource provides biopharma manufacturers with crucial insights into maintaining product integrity through adv... -
News Meeting Critical Deadlines: Custom Assemblies for Viral Vector Manufacturing
Discover how SaniSure delivered 70 custom assemblies in half the standard lead time, supporting vital viral vector manufacturing for a leading CDMO. -
Whitepaper Setting the Cold Standard
Challenges of the freezing processIn biopharmaceutical manufacturing, it is common to bulk-freeze biological drug substance (DS), with target storage temperatures ranging from -20℃ to below -65℃. These temperatures offer a number of benefits – they can stabilize the DS long-term, helping to maximize its shelf life, allowing for bulk storage until needed. Freezing can also help minimize the risk of potential microbial growth in bioburden-controlled DS, as well as circumvent cumulative stability of DS and drug product (DP).Th...